Hypertension: Shall we focus on adipose tissue?

Journal of the American Society of Nephrology

Volumn 21, Issue 7, 2010, Pages 1067-1068

  Bo, Simona ^a   Cavallo Perin, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RESISTIN;

ADIPOSE TISSUE; BLOOD VESSEL WALL; BODY MASS; CARDIOVASCULAR RISK; CELL PROLIFERATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASOCONSTRICTION;

EID: 77954570525     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010050524     Document Type: Editorial

References (19)

1. Wiçcek A, Kokot F, Chudek J, Adamczak M: The adipose tissue: A novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 17: 191-195, 2002 (Pubitemid 34157125)
2. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 409: 307-312, 2001
3. Koerner A, Kratzsch J, Kiess W: Adipocytokines: Leptin - the classical, resistin - the controversial, adiponectin - the promising, and more to come. Best Pract Clin Endocrinol Metab 19: 525-546, 2005
4. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Commun 300: 427-476, 2003
5. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111: 932-939, 2005
6. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA: An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1: e45, 2004
7. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an adipokine with potent proinflammatory properties. J Immunol 174: 5789-5795, 2005 (Pubitemid 40593223)
8. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA: Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interactions. Circulation 108: 736-740, 2003
9. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Yao Q, Chen C: Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 41: 691-698, 2005 (Pubitemid 40637670)
10. Calabro P, Samudio I, Willerson JT, Yeh ET: Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110: 3335-3340, 2004
11. Hung HF, Wang BW, Chang H, Shyu KG: The molecular regulation of resistin expression in cultured vascular smooth muscle cells under hypoxia. J Hypertens 26: 2349-2360, 2008
12. Frankel DS, Vasan RS, D'Agostino RB, Benjamin EJ, Levy D, Wang TJ, Meigs JB: Resistin, adiponectin, and risk of heart failure: The Framingham Offspring study. J Am Coll Cardiol 53: 754-762, 2009
13. Takata Y, Osawa H, Kurata M, Kurokawa M, Yamauchi J, Ochi M, Nishida W, Okura T, Higaki J, Makino H: Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 51: 534-539, 2008
14. Papadopoulos DP, Makris TK, Krespi PG, Poulakou M, Stavroulakis G, Hatzizacharias AN, Perrea D, Votteas VV: Adiponectin and resistin plasma levels in healthy individuals with prehypertension. J Clin Hypertens 7: 729-733, 2005
15. Zhang L, Curhan GC, Forman JP: Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol 21: 1185-1191, 2010
16. Bo S, Ciccone G, Durazzo M, Gambino R, Massarenti P, Baldi I, Lezo A, Tiozzo E, Pauletto D, Cassader D, Pagano G: Efficacy of anti-oxidant treatment in reducing resistin serum levels: A randomized study. PLoS Clin Trials 2: e17, 2007
17. Bo S, Gambino R, Gentile L, Pagano G, Rosato R, Saracco GM, Cassader M, Durazzo M, Cavallo-Perin P: High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: A population-based study. J Hypertens 27: 102-108, 2009
18. Ix JH, Sharma K: Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 21: 406-412, 2010
19. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J: Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 19: 593-599, 2008